First‐line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non‐small cell lung cancer with EGFR exon 20 insertions: Real‐world evidence from China

BACKGROUND: Currently, survival benefit of immunotherapy in advanced non‐small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) is controversial, though it generally indicates poor response and activity. Compared with standard chemotherapy in combination with bevacizumab, first‐line c...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Guangjian, Yang, Yaning, Liu, Runze, Li, Weihua, Xu, Haiyan, Hao, Xuezhi, Li, Junling, Zhang, Shuyang, Xu, Fei, Lei, Siyu, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844624/
https://www.ncbi.nlm.nih.gov/pubmed/35608132
http://dx.doi.org/10.1002/cam4.4852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844624/
https://www.ncbi.nlm.nih.gov/pubmed/35608132
http://dx.doi.org/10.1002/cam4.4852

Ejemplares similares